JP7098325B2 - Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 - Google Patents

Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 Download PDF

Info

Publication number
JP7098325B2
JP7098325B2 JP2017529682A JP2017529682A JP7098325B2 JP 7098325 B2 JP7098325 B2 JP 7098325B2 JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017529682 A JP2017529682 A JP 2017529682A JP 7098325 B2 JP7098325 B2 JP 7098325B2
Authority
JP
Japan
Prior art keywords
cells
amino acid
car
domain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537627A (ja
JP2017537627A5 (OSRAM
Inventor
ジェイ フォーマン，スティーブン
ワン，シウリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2017537627A publication Critical patent/JP2017537627A/ja
Publication of JP2017537627A5 publication Critical patent/JP2017537627A5/ja
Priority to JP2022001433A priority Critical patent/JP7252379B2/ja
Application granted granted Critical
Publication of JP7098325B2 publication Critical patent/JP7098325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017529682A 2014-12-05 2015-12-07 Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 Active JP7098325B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022001433A JP7252379B2 (ja) 2014-12-05 2022-01-07 Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088423P 2014-12-05 2014-12-05
US62/088,423 2014-12-05
PCT/US2015/064303 WO2016090369A1 (en) 2014-12-05 2015-12-07 Cs1 targeted chimeric antigen receptor-modified t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022001433A Division JP7252379B2 (ja) 2014-12-05 2022-01-07 Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞

Publications (3)

Publication Number Publication Date
JP2017537627A JP2017537627A (ja) 2017-12-21
JP2017537627A5 JP2017537627A5 (OSRAM) 2019-01-17
JP7098325B2 true JP7098325B2 (ja) 2022-07-11

Family

ID=55069093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529682A Active JP7098325B2 (ja) 2014-12-05 2015-12-07 Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞
JP2022001433A Active JP7252379B2 (ja) 2014-12-05 2022-01-07 Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022001433A Active JP7252379B2 (ja) 2014-12-05 2022-01-07 Ｃｓ１標的化キメラ抗原受容体修飾ｔ細胞

Country Status (12)

Country Link
US (3) US10821161B2 (OSRAM)
EP (2) EP4219530A1 (OSRAM)
JP (2) JP7098325B2 (OSRAM)
KR (1) KR102558502B1 (OSRAM)
CN (2) CN114085856A (OSRAM)
AU (2) AU2015357485B2 (OSRAM)
BR (1) BR112017011893A2 (OSRAM)
CA (1) CA2969704C (OSRAM)
IL (3) IL290459B2 (OSRAM)
MX (2) MX384964B (OSRAM)
RU (1) RU2727451C2 (OSRAM)
WO (1) WO2016090369A1 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
MA51794A (fr) 2014-04-23 2020-05-06 Juno Therapeutics Inc Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive
CN114085856A (zh) 2014-12-05 2022-02-25 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
RU2732925C2 (ru) 2015-01-26 2020-09-24 Селлектис МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
KR102779944B1 (ko) 2016-04-01 2025-03-13 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
BR112018070159A2 (pt) 2016-04-01 2019-04-30 Kite Pharma, Inc. moléculas de ligação de bcma e métodos de uso das mesmas
TWI691596B (zh) 2016-04-01 2020-04-21 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
MX2018015414A (es) * 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
CN105949324B (zh) * 2016-06-30 2019-08-27 上海恒润达生生物科技有限公司 靶向gpc3的嵌合抗原受体及其用途
EP3518944A4 (en) * 2016-09-30 2020-06-17 Baylor College of Medicine ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
US12083148B2 (en) 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
EP3589295B1 (en) 2017-02-28 2024-09-11 Endocyte, Inc. Compositions and methods for car t cell therapy
US20180280437A1 (en) 2017-03-13 2018-10-04 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
KR20190131061A (ko) * 2017-03-20 2019-11-25 시티 오브 호프 Al 아밀로이드증 치료를 위한 cs1 표적화된 키메라 항원 수용체-변형된 t 세포
TWI890655B (zh) 2017-03-27 2025-07-21 瑞士商赫孚孟拉羅股份公司 改良之抗原結合受體
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US11149073B2 (en) 2017-04-28 2021-10-19 Julius-Maximilians-Universität Würzburg ROR1-specific chimeric antigen receptors (CAR) with humanized targeting domains
EP3661511A1 (en) * 2017-08-01 2020-06-10 Julius-Maximilians-Universität Würzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
IL298699B2 (en) 2017-08-11 2024-01-01 Idac Holdings Inc Traffic steering and switching between multiple access networks
PT3704230T (pt) * 2017-11-01 2024-11-19 Juno Therapeutics Inc Processo para gerar composições terapêuticas de células modificadas
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018369639C1 (en) * 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP2021513839A (ja) 2018-02-16 2021-06-03 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ 改変された多能性幹細胞並びに製造方法及び使用方法
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
MX2020012445A (es) * 2018-05-21 2021-02-09 Biosceptre Aust Pty Ltd Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos.
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
US12281152B2 (en) 2018-08-01 2025-04-22 City Of Hope TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
CN112469734A (zh) * 2018-08-03 2021-03-09 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
MX2021001523A (es) 2018-08-09 2021-05-27 Juno Therapeutics Inc Procesos para generar células modificadas y composiciones de las mismas.
CN120005921A (zh) 2018-12-12 2025-05-16 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
EP4332115A3 (en) 2019-04-03 2024-05-29 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
US20220249560A1 (en) * 2019-05-24 2022-08-11 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
AU2020295715A1 (en) * 2019-06-19 2022-02-17 Julius-Maximilians-Universität Würzburg Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
WO2021226543A2 (en) * 2020-05-08 2021-11-11 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
EP4158030A4 (en) * 2020-05-27 2024-06-26 The Medical College of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
CN114286691B (zh) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
JP7776493B2 (ja) * 2020-08-10 2025-11-26 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク シグレック６結合ポリペプチド
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022206941A1 (zh) * 2021-04-02 2022-10-06 克莱格医学有限公司 Cs1工程化细胞及其组合物
US20250032543A1 (en) * 2021-12-06 2025-01-30 The Children's Hospital Of Philadelphia Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
JP2025512797A (ja) * 2022-03-25 2025-04-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改善されたキメラ受容体
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
CN119019554B (zh) * 2023-05-25 2025-08-12 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060406A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Bioassays
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014179759A1 (en) 2013-05-03 2014-11-06 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59954A1 (en) 1989-08-11 1999-02-22 Amrad Corp Ltd Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
WO2007047829A2 (en) 2005-10-19 2007-04-26 Laboratoires Serono S.A. Novel heterodimeric proteins and uses thereof
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3209571A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US9657091B2 (en) 2012-04-05 2017-05-23 Ac Immune S.A. Humanized tau antibody
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
MX378913B (es) 2014-02-14 2025-03-10 Cellectis Células para inmunoterapia diseñadas para dirigir antígeno presente tanto en células inmunes y células patológicas.
US20170051037A1 (en) 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
CN114085856A (zh) * 2014-12-05 2022-02-25 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
KR20190131061A (ko) * 2017-03-20 2019-11-25 시티 오브 호프 Al 아밀로이드증 치료를 위한 cs1 표적화된 키메라 항원 수용체-변형된 t 세포

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060406A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Bioassays
WO2013123061A1 (en) 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014179759A1 (en) 2013-05-03 2014-11-06 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blood, 2012, Vol.119, No.17, pp.3940-3950
Cellular and Molecular Immunology, 2011, Vol.8, pp.281-284
Leukemia, 2013.10.29, Vol.28, pp.917-927
Molecular Therapy, 2009, Vol.17, No.8, pp.1453-1464

Also Published As

Publication number Publication date
IL252645A0 (en) 2017-07-31
BR112017011893A2 (pt) 2018-07-24
IL290459A (en) 2022-04-01
IL280917A (en) 2021-04-29
JP7252379B2 (ja) 2023-04-04
MX2021008498A (es) 2021-08-19
US20240009288A1 (en) 2024-01-11
US20170360910A1 (en) 2017-12-21
CA2969704A1 (en) 2016-06-09
AU2021200122A1 (en) 2021-03-18
AU2015357485B2 (en) 2020-10-15
IL290459B2 (en) 2023-11-01
JP2017537627A (ja) 2017-12-21
RU2727451C2 (ru) 2020-07-21
US20210170001A1 (en) 2021-06-10
CN114085856A (zh) 2022-02-25
KR20170090495A (ko) 2017-08-07
JP2022051744A (ja) 2022-04-01
US12497440B2 (en) 2025-12-16
US11730797B2 (en) 2023-08-22
IL290459B1 (en) 2023-07-01
EP3227315A1 (en) 2017-10-11
AU2015357485A1 (en) 2017-06-29
CN107429253B (zh) 2021-11-05
MX384964B (es) 2025-03-11
EP3227315B1 (en) 2022-11-23
KR102558502B1 (ko) 2023-07-20
HK1247642A1 (zh) 2018-09-28
CA2969704C (en) 2023-05-02
RU2017121826A (ru) 2019-01-10
EP4219530A1 (en) 2023-08-02
IL252645B (en) 2021-03-25
RU2017121826A3 (OSRAM) 2019-07-17
IL280917B (en) 2022-03-01
US10821161B2 (en) 2020-11-03
CN107429253A (zh) 2017-12-01
AU2021200122B2 (en) 2023-02-23
WO2016090369A1 (en) 2016-06-09
MX2017007250A (es) 2018-02-16

Similar Documents

Publication Publication Date Title
US12497440B2 (en) CS1 targeted chimeric antigen receptor-modified T cells
US20250333471A1 (en) Chimeric Antigen Receptors Targeting HER2
US20230348617A1 (en) Chimeric antigen receptors targeted to psca
JP7085990B2 (ja) クロロトキシンドメインを含むキメラ抗原レセプター
CN110636849A (zh) 用于治疗al淀粉样变的经cs1靶向性嵌合抗原受体修饰的t细胞
HK40074512A (en) Chimeric antigen receptors targeting her2
HK1247642B (zh) Cs1靶向性嵌合抗原受体修饰的t细胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220107

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220314

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220629

R150 Certificate of patent or registration of utility model

Ref document number: 7098325

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150